neuro: pd Flashcards

1
Q

3 cardinal signs

A
  1. Tremor :
    - resting tremor (disappears with movement), increases with stress
  2. Rigidity :
    - ‘ratchet’-like stiffness (cogwheel rigidity); also leadpipe rigidity
  3. Akinesia /bradykinesia :
    -subjective sense of weakness, loss of dexterity, difficulty using
    kitchen tools, loss of facial expression, reduced blinking, difficulty
    getting out of bed/chair, difficulty turning while walking.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

pathology

A

loss of dopaminergic neurons in substantia nigra

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

measuring PD

A

Hoehn and Yahr, staging

Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

non-motor sx

A
  • cognitive impairment
  • psychiatric sx: depression, psychosis
  • sleep disorders
  • autonomic dysfunction: constipation, gi motility, orthostatic hypoTN, sialorrhea
  • fatigue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

early/young onset PD

A

slower disease progression

features:
- less cognitive decline
- earlier motor complications
- dystonia is common initial presentation vs falls and freezing in late-onset

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

which drug used in preference for early/young onset PD?

A

dopamine agonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

predictors of more rapid course

A
  • older onset and rigidity
  • postural instability/ freezing gait
  • dementia
  • assoc comorbidities
  • male sex
  • poor levodopa response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

no treatment of pd has been shown to be

A

neuroprotective
- goal of tx is to manage sx and function
- not to replace dopamine or cure PD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

levodopa: w or wo food?

A

absorption decr w high fat or high protein meals
- separate adm by 2hr

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

why can’t dopamine be used as a treatment?

A

does not cross BBB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

peripheral conversion of levodopa to dopamine

A
  • catalysed by DOPA decarboxylase, MAO, COMT
  • causes n/v, hypotension
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Sinemet

A

1:4 or 1:10
carbidopa:levodopa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Madopar

A

1:10
beserazide:levodopa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

onset of dyskinesia caused by levodopa

A

3-5yrs of initiating treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

dose adj when switching from IR to CR levodopa

A

IR -> CR, incr dose by 25-50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

levodopa ddi

A
  • antidopaminergics: metoclopramide, prochlorpherazine, antipyschotics
  • iron, protein
  • pyridoxine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

dopamine agonists: ergot derivatives

A

bromocriptine, cabergoline, pergolide

lower F, due to extensive first-pass metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

dopamine agonists: non-ergot derivatives

A

ropinirole, pramipexole, rotigotine (transdermal), apomorphine (sc)

19
Q

which dop agonist require dose adj for liver impairment?

A

ropinirole, mainly metabolised by the liver to inactive metabolites

20
Q

which dop agonist require dose adj for renal impairment?

A

pramipexole, excreted largely unchanged in the urine

21
Q

dop agonists adr

A

dopaminergic, peripheral: n/v, orthostatic hypoTN, leg edema

dopaminergic, central: hallucinations (usually visual > auditory), somnolence, day-time sleepiness, compulsive behaviours eg. gambling, shopping, eating, hypersexuality

non-dopaminergic: fibrosis, valvular heart disease

22
Q

fibrosis, ergot or non-ergot DA higher risk?

A

ergot higher risk
- pulmonary, pericardic, retro-peritoneal

  • may be partially reversible upon withdrawal
23
Q

valvular heart disease, ergot or non-ergot DA higher risk?

A

incidence appears greater w ergot derived agents

24
Q

when is DA preferred over levodopa?

A

younger patients, max treatment options and delay onset of levodopa-induced motor complications

25
Q

DA vs levodopa

A

< motor complications, but > hallucinations, sleep disturbances, leg oedema,
orthostatic hypotension

26
Q

DA: place in therapy

A

􀂇 Monotherapy in young-onset PD
􀂇 Adjunct to levodopa in moderate/severe PD
􀂇 Management of motor complications caused by
levodopa
􀂇 Rotigotine patch - ______________
􀂇 Neuroprotection, disease modification??
􀂱 Not proven

27
Q

MAO-A

A

peripheral, NE and 5HT

28
Q

MAO-B

A

central, dopamine

29
Q

MAO-B inhibitors

A

selegiline, rasagiline
- irreversible, short t1/2 but long duration of action (MOA regeneration time: 14-28d)

30
Q

MAO-B inhibitors ddi

A

washout period reco: ssri, snri, tca

pethidine, tramadol
linezolid
dextromethorphan
dopamine
sympathomimetics: nasal decongestants
another MAOi

31
Q

if pt is taking MAO-B inhibitors, advise to avoid

A

tyramine (metabolised by MAO-A and MAO-B)-rich food
- aged cheeses, meat, draft beer, fermented food, banana peel

32
Q

MAO-B inhibitors, place in therapy

A

mono in early stages, or adjunct in later stages

33
Q

Comtan

A

entacapone - selective, reversible COMT inhibitor

must be taken at the same time as levodopa

34
Q

Stalevo

A

levodopa, carbidopa, entacapone

35
Q

entacapone ddi

A

iron, calcium,
􀂱 Avoid concurrent nonselective MAOi (but safe with MAOBi,
caution with selective MAO-Ai)
􀂱 any catecholamine drug
􀂱 Enhance anticoagulant effect of warfarin

36
Q

entacapone adr

A

diarrhea, urine discolouration (orange)

may cause dyskinesia upon initiation: may req a decr in levodopa dose

may also potentiate other dopaminergic effects: orthostatic hypoTN, n/v

37
Q

caution use of entacapone in

A

liver impairment

38
Q

incr glutamataergic activity linked to

A

development of and maintenance of levodopa-induced dyskinesia

Glutamate actives NMDA receptor activity
which activates processes that encourage cell
death - a/w neurotoxicity

39
Q

is amantadine taken OM or ON?

A

2nd dose in afternoon, not at night
- can be stimulating

40
Q

adr of amantadine

A

nausea, light-headedness, insomnia, confusion, hallucinations, livedo reticularis

41
Q

amantadine place in therapy

A

adjunctive or
management of levodopa-induced dyskinesia

42
Q

dose adj of amantadine in

A

renally impaired pt

43
Q
A